Showing results (81-90 of 129) with videos related to

Sort By:
Pageof 13
Bone Marrow Transplantation|June 5, 1998
Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?J Mehta, G Tricot, S Jagannath, et al.
Oncogene|June 6, 2017
Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistanceY Song, S Li, A Ray, et al.
Bone Marrow Transplantation|March 14, 2000
Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan aloneK R Desikan, G Tricot, M Dhodapkar, et al.
Blood|July 4, 2001
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patientsB Barlogie, R Desikan, P Eddlemon, et al.
Transplantation and Cellular Therapy|March 6, 2022
Sustained Hematopoietic Engraftment Potential after Prolonged Storage of Cryopreserved Hematopoietic Stem Cells Used in Salvage Autologous Stem Cell TransplantationSarah S Makhani, Samir P Oza, Ronit Reich-Slotky, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|September 29, 2000
The architectural transcription factor high mobility group I(Y) participates in photoreceptor-specific gene expressionK Y Chau, N Munshi, A Keane-Myers, et al.
Blood|December 24, 1998
Age is not a prognostic variable with autotransplants for multiple myelomaD S Siegel, K R Desikan, J Mehta, et al.
Diabetes Care|November 30, 2012
Assessment of barriers to improve diabetes management in older adults: a randomized controlled studyMedha N Munshi, Alissa R Segal, Emmy Suhl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 1998
Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myelomaK R Desikan, B Barlogie, S Jagannath, et al.
Cancer Chemotherapy and Pharmacology|November 7, 1999
Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic studyS M Grunberg, J Crowley, K R Hande, et al.
Pageof 13